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Abstract: Cerebral palsy (CP) is a catastrophic acquired disease, occurring during   development 
of the fetal or infant brain. It mainly affects the motor control centres of the developing brain, 
but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms 
including lack of communication, epilepsy, and alterations in behavior. Most children with cere-
bral palsy exhibit a short stature, progressively declining from birth to puberty. We tested here 
whether this lack of normal growth might be due to an impaired or deficient growth   hormone 
(GH) secretion. Our study sample comprised 46 CP children, of which 28 were male and 18 
were female, aged between 3 and 11 years. Data obtained show that 70% of these children lack 
normal GH secretion. We conclude that GH replacement therapy should be implemented early 
for CP children, not only to allow them to achieve a normal height, but also because of the 
known neurotrophic effects of the hormone, perhaps allowing for the correction of some of the 
common disabilities experienced by CP children.
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The cumulative incidence rate of cerebral palsy (CP) in the 5–7 year age group is 2.7 
cases for every 1000 live births.1 Apart from motor disabilities, many CP   children dis-
play a number of cognitive and sensorial affectations; among these, mental   disadvantage 
is the most frequent one (IQ , 50), followed by active seizures, unable to walk, and 
blindness. Up to 80% have at least some impairment of speech; half of all children 
have gastrointestinal and feeding problems.2
Major causes for CP include abnormal intrauterine developments, due to fetal-
  maternal infections, asphyxia before birth, hypoxia during delivery, brain trauma dur-
ing labor and delivery, and complications in the perinatal period.3 Apart from these, 
prematurity is responsible for 40%–50% of cases of CP. Periventricular   leucomalacia 
(PVL) and parenchymal venous infarction complicating germinal matrix/intraventricular 
hemorrhage have long been recognized as the two significant white matter diseases 
responsible for the majority of cases of cerebral palsy in survivors of preterm birth. 
However, in more recent studies using magnetic resonance imaging to assess the preterm 
brain, two new appearances have been documented, adding to the spectrum of white 
matter disease of prematurity: punctate white matter lesions, and diffuse excessive high 
signal intensity. These appear to be more common than PVL but less significant in terms 
of their impact on individual neurodevelopment. They may, however, be associated with 
later cognitive and behavioral disorders known to be common following preterm birth.4 
A recent and interesting hypothesis suggest that chronic fetal hypoxemia (CHX) may 
cause fetal brain injury by upregulating   inflammatory cytokine cascades,   culminating in Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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apoptosis pathway activation. Increasing the lactate/pyruvate 
and decreasing the glutathione (GSH)/oxidized glutathione 
(GSSH) ratios, confirms a shift to a pro-oxidant state. The end 
result was a .30% decrease in hippocampal neuron   density. 
Based on a microarray spotted with 113 cytokines and 
receptors, 22 genes were upregulated by CHX in   proportion 
to the degree of hypoxia; the findings were confirmed by 
quantitative polymerase chain reaction. Thus, CHX would 
trigger fetal brain inflammation inversely proportional to its 
severity, characterized by increased   apoptosis and neuronal 
loss. The authors suggest that CHX fetal brain injury is not 
directly caused by oxygen deprivation but rather is an   adaptive 
response that becomes maladaptive.5
Independent of the causal factors responsible for the 
development of CP, the disease has a strong socioeconomic 
impact. There is no cure for CP, and therapeutical approaches 
such as physical therapy, occupational therapy, speech 
therapy, drugs to control seizures, and surgery to correct 
anatomical abnormalities, only report a small benefit for 
affected people. A study carried out in Denmark reveals that 
the lifetime cost of CP stands at about €860,000 for men 
and about €800,000 for women. The largest component was 
social care costs, particularly during childhood.6
Most CP children often have poor linear growth   during 
childhood, resulting in a diminished final adult height.7 However 
the number of studies in which it has been reported whether or 
not GH secretion is impaired in CP is quite limited.7–10 These 
studies reflect that GH provocative testing induced a GH defi-
cient secretion. In a recent study it was indicated that diminished 
circulating IGF-1 and GH concentrations may explain why 
children with CP are smaller than normally growing children.10 
On the other hand, osteopenia is a common finding in children 
with CP, and seems to be associated with decreased IGF-1 
and IGFBP3 plasma levels, usual markers of deficient GH 
secretion.11 The large percentage of CP children with GH defi-
ciency has been reported to be noteworthy.9   However, given the 
complexity of GH neurorregulation12 it seems to be logical that 
severe brain damage may affect a number of neurotransmitter 
pathways involved in GH control, thus affecting the normal 
secretion of the hormone. Other   possible causes of decreased 
growth in CP include psychosocial deprivation and suboptimal 
nutritional status,9 but these are also involved in subnormal GH 
secretion.12
In few studies have the benefits of GH-replacement 
therapy in children with CP been reported, and most of these 
studies only reflect the increased growth observed during the 
treatment period with the hormone.7,8,13 Findings gained in a 
recent study indicate that 18 months of GH therapy in   children 
with CP is associated with significant improvements in bone 
mineral density, as well as increased linear growth.13
Our objective in this study was to assess whether GH 
secretion is affected in children with CP, and to establish 
the degree of this impaired GH secretion in a large sample 
of the CP population.
Method
Our sample included 46 CP children (28 male, 18 females) 
aged 3 to 11 years old, who attended the Medical Center 
Proyecto Foltra for physical and cognitive rehabilitation. 
Table 1 shows the presumed causes of CP, while Table 2 
shows the disabilities found at admission according to the 
study carried out by Malkowicz et al.14
Clinical examinations include measurements of height 
and weight, and the examination of growth velocity on 
their pediatric card (if provided), and Tanner stage of sexual 
maturation. MRI or CT scans of the brain performed prior 
to their initial evaluations were used to document the extent 
of white and gray matter damage. Blindness was confirmed 
by evoked visual potentials analysis.
A blood sample analysis was performed for routinary 
hemathological and biochemistry parameters. Anterior pitu-
itary hormones baseline secretion and plasma levels of fT4 
were measured by chemiluminiscents assays. In addition, 
fasting plasma IGF-1 and IGFBP3 were measured using a 
solid-phase, enzyme-labeled chemiluminiscent immunomet-
ric assay (Inmulite 2000, Siemens).
To study whether or not GH secretion was deficient, an 
insulin-induced hypoglycemia test was performed for 12 of 
the CP children.
Results
Ferropenic anemia was found in 55% of the children studied. 
Additionally, most of the children showed normal pituitary 
function with the only exception being GH secretion, which 
was shown to be impaired in 26% of the patients accord-
ing to the GH peak (,9 ng.mL-1, 12 patients) in response 
to hypoglycemia and plasma IGF-I and IGFBP3 values. 
These correlated well (P , 0.01) with diminished growth 
Table 1 Presumed causes of cerebral palsy in the children studied
Cause Number Incidence (%)
Perinatal hypoxia 22 47.8
Prematurity 14 30.4
Prenatal asphyxia 4 8.7
Prenatal infections 3 6.5
Postnatal encephalitis 3 6.5Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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velocity (,5 cm per year) and low stature (under percen-
tile 3, P3) for their chronological age. However, for 13% 
of patients in whom GH secretion had not been studied, 
plasma IGF-I and IGFBP3 values were shown to be normal 
according to the laboratory range, although these values were 
very close to the lower limits of normality. These appar-
ently normal values did not correlate with the short stature 
found in these children, all of them under P3 of height for 
his chronological age. In another 31% of patients, plasma 
IGF-1 and IGFBP3 were under the normal values for their 
ages. Thus, in total, 70% of the patients studied seemed to 
have deficient GH secretion.
Subclinical hypothiroidism was found in seven patients, 
and a premature adrenarche was found in one patient. One of 
the children was shown to have an increased PRL secretion 
(35 ng.mL-1). FSH and LH secretion was normal in all but 
one of the patients studied (the patient with premature adrenar-
che), ranging from undetectable to prepubertal values, and 
correlated with chronological age and Tanner stage of sexual 
maturation.
Tanner stage of sexual maturation ranged between 1 and 
3 and body mass index (BMI) was lower than normal in 52% 
of CP children. These results are shown in Table 3.
Discussion
Our results show that impaired GH secretion is the most 
frequent anterior pituitary abnormality in CP children, 
independent of the causes leading to the disease. The GH 
response to provocative tests was studied only in 12 CP but 
we measured in all the patients plasma IGF-I and IGFBP3 
values, usually considered to be a clear indicative about how 
GH secretion occurs.11
Despite the fact that we used a cross-sectional design 
and were unable to accurately test this, it seems that there 
is a continuum in the decrease in growth velocity leading 
to a final short height. This sort of trial design only allows 
for evaluation of the prevalence but not the incidence of a 
certain affectation, such as decreased gowth velocity and GH-
deficiency. A longitudinal study would allow more significant 
data to be gained. Despite this, decreased growth velocity in 
CP children could be attributed to several causes. Of these, 
one cause may be the shortening of flexor tendons, due to 
the lack of muscular cerebral control, but this should be 
responsible for causing only a slight decrease in final height. 
Other causes include suboptimal psychosocial deprivation 
and nutritional status.9 Spasticity might also be responsible 
because of increased caloric expenditure due to the excessive 
and continuous muscle contraction in spastic CP children.
IGF-I is responsible for most of the GH effects on lon-
gitudinal growth, but not all of them. GH is released from 
the pituitary soon after birth; however the hormone does not 
play a significant role on longitudinal growth during the first 
year of life. Nutritional status is the main factor for growing 
during this period of life by increasing hepatic IGF-I synthesis 
and release.12 In some situations deficient GH secretion is 
not accompanied by low plasma IGF-I values; this can be 
observed in obese children. Childhood obesity is character-
ized by normal or even accelerated growth in spite of reduced 
growth hormone (GH) secretion, while plasma IGF-I levels 
are normal.15,16 A clear divergence between GH secretion 
and plasma IGF-I has been reported recently in amyotrophic 
lateral sclerosis patients; where a marked or severe GH defi-
ciency exists, IGF-I is significantly higher in these patients 
than in matched healthy controls.17 Conversely, in anorexia 
nervosa patients, low circulating IGF-I levels are associated 
with enhanced GH production rate.18,19 Thus, a normal plasma 
IGF-I value can not exclude a deficient GH secretion.
There is a clear reluctance in Spain, and perhaps other 
countries, to prescribe GH treatment for children with CP 
when GH deficiency has been diagnosed. A clear reluctance 
exists too for studying whether or not GH secretion is defi-
cient in CP children. The reasons given are based on the 
lack of benefits that growth brings to a child with serious 
neurological problems.
However, we know today that GH plays a very important 
role at the central level.
The growth hormone insulin-like growth factor-1 system 
induces neurogenesis and increases brain plasticity.20 GH 
and IGF-1 are expressed in the brain21,23 and both hormones 
can cross the blood-brain barrier.23 The GH receptor (GH-R) 
and the IGF-1 receptor (IGF-1-R) are widely expressed in 
several zones of the rodent and human brain, including the 
hippocampus.24–29 In particular, GH, GH-R, and IGF-1-R are 
Table 2 Disabilities found at admission
Disability Number Prevalence (%)
Motor disabilities1 45 97.8
impairment of speech 36 78.2
gastrointestinal problems 36 78.2
Mental disadvantage 35 76
seizures2 22 47.8
Visual affectations 15 32.6
Lack of speech 5 10.8
Blindness 3 6.5
Notes: The prevalence is related with every specific disability observed. Most of 
the children presented two or more of these disabilities. 1Motor disabilities reflect 
either hypotonic or spastic states.  2seizures had been treated with one or more 
antiepilepsy drugs.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 3 Biochemical data, Tanner’s stage, height percentile (P) and BMi of the patients studied
Patient number Age (years) GH peak (ng.mL-1) IGF-1 (ng.mL-1) IGFBP3 (μg.mL-1) Tanner stage P BMI Kg.(m2)-1
1 3 nP 24 2.6 1 ,3 17
2 3.5 nP 55 3.2 1 15 16.5
3 3.5 nP 96 4.8 2 45 21.5
4 4 nP 26 2.8 1 ,3 17
5 4 nP 45 3.4 1 ,3 19
6 4 nP 52 3.7 1 10 18.5
7 4.5 nP 52 3.6 1 ,3 20
8 4.5 nP 58 3.5 1 ,3 20.5
9 4.5 4.2 25 2.3 1 ,3 16.5
10 5 nP 62 3.8 1 ,3 18
11 5 3.7 31 2.7 1 ,3 18
12 5 nP 115 3.9 1 55 21
13 5 nP 89 3.7 1 40 22
14 5 7.5 35 2.5 1 ,3 16.5
15 5 5.3 39 2.7 1 ,3 16
16 5.5 nP 61 3.9 1 ,3 18
17 5.5 nP 34 2.7 1 ,3 17
18 5.5 2.8 27 2.7 1 ,3 18
19 5.5 4.7 37 2.9 1 ,3 16.5
20 5.5 nP 49 3.4 1 ,3 17
21 5.5 6.2 32 3.1 1 ,3 15.5
22 6 2.1 25 2.5 1 ,3 17.5
23 6 5.8 36 2.4 1 ,3 17
24 6 nP 41 2.7 1 ,3 16.5
25 6 nP 38 3 1 ,3 18
26 6 nP 125 4.3 1 10 21
27 6 nP 29 2.6 1 ,3 17.5
28 6 2.1 25 2.2 1 ,3 16.5
29 6.5 nP 36 3.1 1 ,3 18
30 6.5 5.2 32 3 1 ,3 18.5
31 6.5 6.8 37 3.2 1 ,3 16
32 6.5 nP 137 3.9 1 15 21
33 6.5 nP 34 3.2 1 ,3 16.5
34 6.5 nP 123 4.6 1 15 19
35 7 nP 40 3.2 1 ,3 17.5
36 7 nP 125 4.5 1 15 21
37 7 nP 163 4.8 1 25 22.5
38 7.5 nP 183 5.1 2 35 21.5
39 7.5 nP 98 4.1 1 15 17.5
40 8 nP 76 3.9 1 10 18
41 8 nP 45 3.4 1 ,3 17.5
42 9 nP 41 3.2 1 ,3 17
43 9 nP 166 4.3 2 15 20
44 9.5 nP 48 3.2 2 ,3 17
45 10 nP 43 2.9 2 ,3 17.5
46 11 nP 55 2.7 3 ,3 16
Lower limits for age.- igF-1: 42 ng.mL-1 (3–5 years), 88 ng.mL-1 (6–8 years), 110 ng.mL-1 (9–11 years). igFBP3: 3.4 μg.mL-1. BMi: 18 Kg.(m2)-1.
expressed in hippocampal neural progenitors, acting on the 
proliferation and differentiation of these neural stem cells.30,31 
Thus, besides its major role in several metabolic processes, 
the GH-IGF-1 axis has multiple and important neurotrophic 
effects, related to cell proliferation and survival, both in the 
central and peripheral nervous systems.20,23 According to this, 
GH-R expression is increased in the subventricular zone after 
focal ischemia32 and GH has been demonstrated to increase 
cell proliferation in the hippocampus of adult hipophysec-
tomized rats.33 Similarly, IGF-1 increases cell proliferation 
in hippocampal cells30,34 and its expression is increased in 
the affected brain hemisphere after an ischemic injury.35,36 Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  Neuropsychological assessments have demonstrated that 
GHD is associated with reduced cognitive performance; 
specifically, in the majority of studies it has been found that 
GHD can lead to clinically relevant changes in memory, pro-
cessing speed, attention, vocabulary, perceptual speed, spatial 
learning, and in reaction time tests.37–43 Cognitive dysfunc-
tion appears to be specifically related to GH deficiency; this 
hypothesis is supported by the positive correlations between 
serum IGF-I concentration and IQ, whereas poorer emotional 
well-being and reduced perceptual-motor performance are 
attributed to other pituitary hormone deficiencies.37 In this 
sense, in previous studies it has been show that hormone 
replacement therapy in GHD patients did not improve psy-
chological well-being or perceptual-motor skills.37,44 Thus, 
although the number of reliable intervention studies is lim-
ited, overall it appears that cognitive disorders secondary to 
GHD may be reversed by GH replacement.39,40 Some authors 
have suggested that the effects that GH has in the modifica-
tion of the concentration of different neurotransmitters in the 
cerebrospinal fluid (CSF) may be important. GH substitutive 
treatment decreases the dopamine metabolite homovanil-
lic acid, as do trycyclic antidepressants or the monoamine 
oxidase inhibitors, and increases by about 30% the levels of 
aspartate, a neurotransmitter with important effects in terms 
of the hippocampal long-term potentiation and in attentional 
functions.45,46
Most of these studies have been carried out in adult GH-
deficient patients and rodents, but given the high plasticity of 
the brain during childhood there is no reason to assume that 
they could not achieve similar results in children.
According to these and given the high incidence of GH-
deficiency in CP children that we observed in this study, we 
propose that GH replacement therapy should be started as 
early as possible, together with specific rehabilitation, once 
CP is detected; the conjunction of GH therapy and reha-
bilitation has the potential to prevent or correct most of the 
disabilities seen in these children.
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